PLACID trial proves Plasma therapy for Covid-19 inefficient
- Posted By
10Pointer
- Categories
Health Issues
- Published
3rd Nov, 2020
-
- Recently, the PLACID Trial, a multicentre randomized controlled trial (RCT), has shown that convalescent plasma (CP) therapy for Covid-19 patients gave no positive effects and did not improve the outcome of the patients.
- The trial results indicate that there was no difference in the 28-day mortality.
- Progression of Covid-19 from moderate to severe in patients treated with CP along with basic standard care had no difference when compared to basic standard care alone.
- The use of CP seemed to improve the resolution of shortness of breath and fatigue in patients with moderate Covid-19.
- However, this did not translate into a reduction in 28-day mortality or progression to severe disease.
- The ICMR is now considering removing the option of CPT from the national guidelines.
- Convalescent Plasma, extracted from the blood of patients recovering from an infection, is a source of antibodies against the infection.
- The therapy uses blood from people who have recovered from an illness to help others recover.
- PLACID Trial was conducted by the Indian Council of Medical Research (ICMR). It is the first and largest randomized control trial to be completed in the world.
